Physician profile
Jenny Tan
NPI 1598250136
$1,458.71
in general payments reported to CMS, 2019-2025
10 companies · $98.98 in 2025
The $98.98 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $192 · 2020: $101 · 2021: $55.03 · 2022: $297 · 2023: $279 · 2024: $436 · 2025: $98.98.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $794 · Consulting Fee: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $793.67 |
| Consulting Fee | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $424.84 | 2020-2024 | Precision 7, Total30, Precision 1 |
| Gilead Sciences, INC. | $196.87 | 2023 | |
| Johnson & Johnson Vision Care, INC. | $172.10 | 2020-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $157.74 | 2019 | |
| Bausch & Lomb Americas INC. | $152.67 | 2024 | Infuse, Vyzulta, Miebo |
| Johnson & Johnson Surgical Vision, INC. | $138.20 | 2019-2022 | |
| Coopervision INC. | $132.12 | 2019-2025 | Myday Contact Lens, Clariti Contact Lens, Misight Contact Lens |
| Dompe US, INC. | $34.40 | 2024 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $29.77 | 2024 | Xdemvy |
| Biotissue Holdings INC. | $20.00 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jenny Tan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.